| Title |
RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
|
|---|---|
| Published in |
Trials, November 2018
|
| DOI | 10.1186/s13063-018-2996-6 |
| Pubmed ID | |
| Authors |
Sean H. Lim, Kim M. Linton, Graham P. Collins, Joke Dhondt, Joshua Caddy, Liz Rossiter, Karan Vadher, Keira Fines, Laura E. Rogers, Diana Fernando, Louise Stanton, Andrew J. Davies, Peter W. M. Johnson, Gareth Griffiths |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 83% |
| Unknown | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 12% |
| Student > Master | 5 | 12% |
| Student > Postgraduate | 4 | 10% |
| Student > Ph. D. Student | 3 | 7% |
| Student > Bachelor | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 17 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 12% |
| Immunology and Microbiology | 3 | 7% |
| Sports and Recreations | 3 | 7% |
| Nursing and Health Professions | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 6 | 14% |
| Unknown | 21 | 50% |